NCT06889064View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

October 8, 2024

Study Completion Date

October 8, 2024

Conditions
Essential Hypertension
Interventions
DRUG

BR1400-1

One tablet administered alone

DRUG

BR1400-2

One tablet administered alone

DRUG

BR1400-3

One tablet administered alone

Trial Locations (1)

Unknown

Seoul Bumin Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY

NCT06889064 - A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter